OpinionOpen Access

Efficacy and Safety of Pitavastatin in Menopausal Women with Dyslipidemia

Volume 4 - Issue 1

**Atsushi Imai*, Satoshi Ichigo, Hiroshi Takagi, Ichiro Kawabata, KazutoshiMatsunami and Masashi Hori**

Author Information Open or Close
- Department of Obstetrics and Gynecology, Institute of Endocrine-Related Cancer, Japan
*Corresponding author: Atsushi Imai, Department of Obstetrics and Gynecology, Institute of Endocrine-Related Cancer, Matsunami General Hospital, Kasamatsu, Gifu 501-6062, Japan

Received: April 11, 2018; Published: April 20, 2018

DOI: 10.26717/BJSTR.2018.04.000983

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Dyslipidemia is highly common in women, particularly after the menopause. Menopause, caused by ovarian dysfunctions, is be associated with an increase in total and low-density lipoprotein-cholesterol (LDL-C) and a decrease in high density lipoprotein-cholesterol (HDL-C). Pitavastatin (2 mg/day, orally), one of new generation statin, in addition to its strong LDL-C lowering effect, revealed a higher efficacy to increase HDL-C level and improved elevated triglyceride (TG) level in Japanese peri- and postmenopausal women. Pitavastatin may be an effective treatment option in (post-)menopausal women with dyslipidemia, in conjunction with suggested lifestyle modification.

Keywords: Pitavastatin; Dyslipidemia; Low-Density Lipoprotein-Cholestero;, High Density Lipoprotein-Cholesterol; Triglyceride

Abstract| Opinion| References